Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 18/20 | 0.45 |
| ▸ | CCND1 | P24385 | 7/20 | 0.45 |
| ▸ | CDK2 | P24941 | 4/20 | 0.45 |
| ▸ | CDK6 | Q00534 | 6/20 | 0.43 |
| ▸ | CDK1 | P06493 | 3/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 3/20 | 0.40 |
| ▸ | CCND2 | P30279 | 2/20 | 0.40 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915902 | 1.00 | CDK4 (0.45) | CDK4CCND1CDK2CDK6CDK1 | |
| SCHEMBL14915791 | 1.00 | CDK4 (0.45) | CDK4CCND1CDK2CDK6CDK1 | |
| SCHEMBL29742006 | 0.88 | CDK4 (0.48) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL1393033 | 0.88 | CDK4 (0.48) | CDK4CCND1CDK2CCNA2CCNA1 | |
| SCHEMBL1394175 | 0.86 | BTK (0.40) | CDK4CCND1BTKCCND3CCND2 | |
| SCHEMBL14915752 | 0.85 | BTK (0.48) | CDK4CCND1CDK2CDK6CCNA2 | |
| SCHEMBL14916553 | 0.85 | BTK (0.48) | CDK4CCND1CDK2CDK6CCNA2 | |
| SCHEMBL14915751 | 0.85 | BTK (0.48) | CDK4CCND1CDK2CDK6CCNA2 | |
| SCHEMBL14924365 | 0.84 | BTK (0.39) | CDK4CCND1CDK2CDK6CCNA2 | |
| SCHEMBL170959 | 0.83 | SYK (0.42) | CDK4CCND1BTKCCND3CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4050012-A1 | PYRIDONE BORONATES FOR THE PREPARATION OF INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-08-31 | — | — | EP | disclosed |
| EP-4019508-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3521288-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2021-09-08 | — | — | EP | disclosed |
| EP-3521288-A1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2019-08-07 | — | — | EP | disclosed |
| EP-3002284-B1 | HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2019-05-22 | — | — | EP | disclosed |
| EP-2773639-B1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| EP-2773639-B1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9115152-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8946213-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2773639-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729072-B2 | Alkylated piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2014-05-20 | — | — | US | disclosed |
| WO-2013067277-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | CDK4 463/4885CCND1 1461/4885CDK2 170/4885 |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | CDK4 747/4885CCND1 2545/4885CDK2 280/4885 |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | CDK4 463/4885CCND1 1461/4885CDK2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.